Clinical Trial Detail

NCT ID NCT03904251
Title CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Indications

acute myeloid leukemia

Therapies

CPX-351 + Gemtuzumab ozogamicin

Age Groups: adult senior

No variant requirements are available.